InvestorsObserver is giving Kintara Therapeutics Inc (KTRA) an Analyst Rating Rank of 5, meaning KTRA is ranked higher by analysts than 5% of stocks. The average price target for KTRA is $250 and analyst’s rate the stock as a Hold.
Wall Street analysts are rating KTRA a Hold today. Find out what this means to you and get the rest of the rankings on KTRA!